Boom Forum SF: AI x Bio Outlook

Boom Forum brings you face to face with the technologists defining this decade.

This exclusive gathering is for Limited Partners. The best service we can offer LPs is to make them smarter about the world - to see what we see every day. With the launch of Boom Fund III, we invite you to our inner circle.

Join us for an exclusive, intimate discussion on the 2026 Outlook for AI x Bio with Jorge Reis-Filho, the Chief of AI for Science Innovation, Enterprise AI Unit, Astra Zeneca. Over breakfast, Jorge will share an off-record conversation to give you the Bio Outlook for 2026: how advances in artificial intelligence, foundation models, and programmable biology are reshaping the future of drug discovery, oncology care, and human longevity.

Space is extremely limited and exclusive for Limited Partners.

-----

About Boom Capital

Boom Capital backs the scientists and founders building the future before it’s understood. Our portfolio includes: Swarm Technologies (acquired by SpaceX), Astra (NASDAQ: ASTR), Planet (NYSE: PL), Impulse Space (founded by the CTO of SpaceX), and The Vaccine Company (acquired by Eli Lilly for $1.55 Billion).

Spun out of Eric Schmidt’s venture firm, Innovation Endeavors, and founded by Celestine Schnugg, Boom is an early investor in frontier technologies sourced through our in-house scientific society.

About Jorge Reis-Filho

Dr. Jorge Reis-Filho is the Chief of AI for Science Innovation within the Enterprise AI Unit at AstraZeneca, where he leads high-impact initiatives to transform drug discovery and clinical development through advanced foundation models and agentic frameworks. A pioneer at the intersection of medicine and technology, his career spans groundbreaking work in molecular pathology, genomics, and artificial intelligence.

An internationally-recognized leader in oncology and computational pathology, Dr. Reis-Filho’s contributions have been honored with prestigious accolades, including the MSKCC William Gerald Award (2024) and the BCRF Larry Norton Award (2023). For forward-looking investors, he offers a rare blend of deep domain expertise, a proven track record of scaling biomedical AI, and a visionary approach to building the next generation of AI-native scientific workflows.

About Celestine Schnugg

Cee Cee is the Founding Managing Partner of Boom Capital, an early stage venture firm investing in the top 200 technologists of this decade.

Prior to spinning out the firm from Eric Schmidt's Innovation Endeavors, she helped build the emerging technology sustainability program at Apple. Celestine is on the Investment Committee of the Goldhirsh Foundation and supports The Cancer Interception Foundation & Project Atlas, building the top 10 biobanks of this decade to cure all diseases.

Boom will be holding the second close of Boom Capital Fund III ($50MM target). Read updates on the firm here.